T1	p 33 39	adults
T2	p 230 262	31 adult asthmatic patients in a
T3	i 46 87	sodium cromoglycate pressurized aerosol :
T4	i 122 212	Sodium cromoglycate formulated as a pressurized aerosol ( 2 mg 4-times daily ) and placebo
T5	i 311 330	Sodium cromoglycate
T6	i 347 354	placebo
T7	i 769 790	sodium cromoglycate .
T8	i 811 878	bronchodilators ( theophylline and aerosol beta-stimulants combined
T9	i 933 962	sodium cromoglycate treatment
T10	i 975 982	placebo
T11	i 1053 1105	sodium cromoglycate delivered by pressurized aerosol
T12	i 1136 1143	placebo
T13	o 358 390	improving breathlessness at rest
T14	o 415 443	breathlessness on exertion (
T15	o 471 489	quality of sleep (
T16	o 538 579	morning peak expiratory flow rate value (
T17	o 650 662	clinicians '
T18	o 988 1000	side-effects
T19	o 1168 1186	asthmatic symptoms
T20	o 1214 1220	amount